How to interpret her comments regarding another trial in regional hospitals? Would this expanded access be part of a potential Phase 3 trial or another Phase 2 trial treating a wider pool of stroke patients ie not only mechanical thrombectomy and/or possible preparation for label expansion should the drug be approved?
AGN Media thread, page-102
Add AGN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
71.5¢ |
Change
-0.015(2.05%) |
Mkt cap ! $91.58M | |||
| Open | High | Low | Value | Volume |
| 74.0¢ | 75.0¢ | 71.0¢ | $134.2K | 183.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 77175 | 71.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 75.0¢ | 12000 | 1 |
View Market Depth
| Last trade - 16.10pm 19/11/2024 (20 minute delay) ? |
| AGN (ASX) Chart |